Insights

Gathering insights about Oculi…

Similar companies to Oculi

Oculi Tech Stack

Oculi uses 8 technology products and services including Wix, Open Graph, Sirvoy, and more. Explore Oculi's tech stack below.

Wix
Content Management System
Open Graph
Content Management System
Sirvoy
Hotel Management
RequireJS
Javascript Frameworks
Verilog
Programming Languages
Onsen UI
Software Development
X-Content-Type-Options
Web & Portal Technology
HTTP/3
Web & Portal Technology

Media & News

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
ZUG, Switzerland, May 15, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company, the annual equity incentive awards granted to directors of the Company, and the one-time equity incentive award granted to a new director upon his election to the board of directors of the Company.
May 15, 2026 | www.globenewswire.com
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
ZUG, Switzerland, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2026 Annual General Meeting held on May 13, 2026 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 12:00 p.m. CEST, including the election of Gregory D. Perry to its Board of Directors.
May 14, 2026 | www.globenewswire.com
Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $0.77 per share a year ago.
May 11, 2026 | www.zacks.com
Oculis Reports Q1 2026 Financial Results and Provides Company Update
ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pipeline Advancing as Planned, Leading with OCS-01 Key Milestone Completion of LPLV in Both DIAMOND Phase 3 Trials; Data Readout on Track for June 2026 Licaminlimab PREDICT-1 Trial in Active Site Recruitment Phase, Pioneering a Genotype-Driven Path to Precision Medicine in Dry Eye Disease Privosegtor Regulatory Path Cleared via FDA SPA; PIONEER-1 Phase 3 Trial Advances with Ongoing Site Activation Cash, cash equivalents, and short-term investments of $277.6 million as of March 31, 2026, providing cash runway into 2H 2029 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced results for the first quarter ended March 31, 2026, and provided an overview of the Company's progress. Riad Sherif, M.D.
May 11, 2026 | www.globenewswire.com
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
ZUG, Switzerland, May 07, 2026 (GLOBE NEWSWIRE) -- Special Protocol Assessment (SPA) agreement with the U. S. FDA provides regulatory alignment on the registrational path for Privosegtor in optic neuritis (ON) FDA Breakthrough Therapy and EMA PRIME designations in ON underscore the significant unmet need and therapeutic potential of Privosegtor as a neuroprotective candidate Oculis Holding AG (Nasdaq: OCS / XICE: OCS) ("Oculis"), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that it has received written agreement from the U.
May 07, 2026 | www.globenewswire.com
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
Special Protocol Assessment (SPA) agreement with the U. S. FDA provides regulatory alignment on the registrational path for Privosegtor in optic neuritis (ON)FDA Breakthrough Therapy and EMA PRIME designations in ON underscore the significant unmet need and therapeutic potential of Privosegtor as a neuroprotective candidate ZUG, Switzerland, May 7 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) ("Oculis"), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that it has received written agreement from the U.
May 07, 2026 | www.globenewswire.com
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
ZUG, Switzerland, May 7 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that it has received written agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) regarding PIONEER-1, the first registrational trial within the PIONEER Program evaluating Privosegtor for the treatment of optic neuritis (ON). This formal FDA agreement confirms the design and planned analysis of the PIONEER-1 study are adequate to address the objectives necessary to support a future NDA submission, subject to a successful trial outcome and FDA review of the complete submission.
May 07, 2026 | www.globenewswire.com

Oculi's Email Address Formats

Oculi uses at least 1 format(s):

Oculi Email Formats	Example	Percentage
First.Last@oculi.ai	John.Doe@oculi.ai	100%

Frequently Asked Questions

Where is Oculi's headquarters located?

Oculi's main headquarters is located at 260 East Main Street Suite 6325 Rochester, New York United States. The company has employees across 4 continents, including North AmericaAsiaOceania.

What is Oculi's stock symbol?

Oculi is a publicly traded company; the company's stock symbol is OCS.

What is Oculi's official website and social media links?

Oculi's official website is oculi.ai and has social profiles on LinkedIn.

What is Oculi's NAICS code?

Oculi's NAICS code is 3344 - Semiconductor and Other Electronic Component Manufacturing.

How many employees does Oculi have currently?

As of April 2026, Oculi has approximately 14 employees across 4 continents, including North AmericaAsiaOceania. Key team members include Chief Technical Product Officer: F. B.Founder Ceo: C. R.Office Manager: S. K.. Explore Oculi's employee directory with LeadIQ.

What industry does Oculi belong to?

Oculi operates in the Semiconductor Manufacturing industry.

What technology does Oculi use?

Oculi's tech stack includes WixOpen GraphSirvoyRequireJSVerilogOnsen UIX-Content-Type-OptionsHTTP/3.

What is Oculi's email format?

Oculi's email format typically follows the pattern of First.Last@oculi.ai. Find more Oculi email formats with LeadIQ.

When was Oculi founded?

Oculi was founded in 2019.

Oculi

Q: What is Oculi's official website and social media links?

Oculi's official website is oculi.ai. Oculi has social profiles on LinkedIn.

Q: How many employees does Oculi have currently?

Oculi has approximately 14 employees.

Q: What technology does Oculi use?

Oculi's tech stack includes X-Content-Type-Options, Webpack, WebsiteBuilder, Wix, PHP.

Q: What is Oculi's NAICS code?

Oculi's NAICS code is 3344 (Semiconductor and Other Electronic Component Manufacturing).

Semiconductor ManufacturingNew York, United States11-50 Employees

Oculi® is a deep-tech, fabless semiconductor company that produces the OCULI SPU™ (Sensing & Processing Unit), a disruptive architecture and product in the world of AI and real-time video processing. The OCULI SPU™ delivers Real-Time Visual AI at the edge where our price to performance increases exponentially within those constraints.

Company Overview

Headquarters: 260 East Main Street Suite 6325 Rochester, New York United States
Website: oculi.ai
Stock Symbol: OCS
NAICS Code: 3344 - Semiconductor and Other Electronic Component Manufacturing
Founded: 2019
Employees: 11-50

Media & News

Funding & Financials

$1M$10M
Oculi's revenue is estimated to be in the range of $1M$10M

Funding & Financials

$1M$10M
Oculi's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Oculi

Smart Eye

Affectiva

Kairos Society

iMotions

Seeing Machines

Oculi Tech Stack

Media & News

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors

Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates

Oculis Reports Q1 2026 Financial Results and Provides Company Update

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

Oculi's Email Address Formats

Frequently Asked Questions

Where is Oculi's headquarters located?

What is Oculi's stock symbol?

What is Oculi's official website and social media links?

What is Oculi's NAICS code?

How many employees does Oculi have currently?

What industry does Oculi belong to?

What technology does Oculi use?

What is Oculi's email format?

When was Oculi founded?

Oculi

Company Overview

Media & News

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors

Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?